Journal of Oncology Research & Treatments

Commentary Open Access

Investigating the Genetic Causes of Cancer using Oncogenes' Strength

Emilia Heinrich*

Department of Medicine and Health Science, University of Freiburg, Freiburg im Breisgau, Germany

***Corresponding author:** Emilia Heinrich, Department of Medicine and Health Science, University of Freiburg, Freiburg im Breisgau, Germany, E-mail: heinrich38@yahoo.com

Received: 28-Apr-2023, Manuscript No. AOT-23-100366; **Editor assigned:** 01-May-2023, PreQC No. AOT-23-100366 (PQ); **Reviewed:** 15-May-2023, QC No. AOT-23-100366; **Revised:** 22-May-2023, Manuscript No. AOT-23-100366 (R); **Published:** 29-May-2023, DOI: 10.4172/aot.1000221

Citation: Heinrich E (2023) Investigating the Genetic Causes of Cancer using Oncogenes' Strength. J Oncol Res Treat. 8:221.

Description

Cancer, a complex and devastating disease, continues to show a significant challenge to the field of medicine. Over the years, extensive research has revealed the critical role played by oncogenes, which are specific genes that have the potential to transform normal cells into cancerous ones. Understanding the structure, function, and regulation of oncogenes has revolutionized our comprehension of cancer biology, easy way for targeted therapies and personalized medicine. This article aims to delve into the fascinating world of oncogenes, exploring their origins, mechanisms of action, and their implications in cancer development and treatment. Oncogenes can arise through various mechanisms, including the activation of proto-oncogenes, viral integration, or chromosomal rearrangements. Proto-oncogenes are normal genes involved in regulating cellular processes such as cell division, growth, and differentiation. Mutations or alterations in these proto-oncogenes can lead to their conversion into oncogenes, resulting in uncontrolled cell growth and the initiation of tumorigenesis. Viral integration occurs when certain oncogenic viruses integrate their genetic material into the host genome, disrupting normal cellular functions. Chromosomal rearrangements, such as translocations or inversions, can also bring oncogenes into close proximity with highly active regulatory elements, leading to their aberrant activation.

Oncogenes can be activated through diverse mechanisms, each resulting in the dysregulation of cellular processes. Point mutations, the most common type of oncogenic alteration, involve changes in single nucleotides within the gene sequence. These mutations can lead to the production of hyperactive proteins, loss of negative regulation, or altered protein stability. Another mechanism involves gene amplification, where multiple copies of the oncogene are generated, resulting in increased expression levels and enhanced activity. Additionally, chromosomal rearrangements can bring together separate genetic elements, creating fusion oncogenes that encode hybrid proteins with novel functions. The activation of oncogenes plays a crucial role in driving the development and progression of various types of cancer. By disrupting the delicate balance between cell proliferation and cell death, oncogenes facilitate uncontrolled cell growth growth and tumor formation. Oncogenes can impact key cellular processes such as cell cycle regulation, DNA repair mechanisms, and apoptosis. For instance, the Ras family of oncogenes promotes cell division by perpetuating growth signals, while the *MYC* oncogene enhances cell proliferation and survival. Other well-known oncogenes, such as *HER2* and *BCR-ABL*, have been implicated in breast cancer and chronic myelogenous leukemia, respectively.

The discovery and characterization of oncogenes have led to the development of targeted therapies that aim to specifically inhibit the activity of these genes. These therapies hold great promise for personalized cancer treatment, as they can selectively target the molecular drivers of each individual's tumor. One approach involves the use of small molecule inhibitors that disrupt oncogene activity. For example, tyrosine kinase inhibitors, such as imatinib, have shown remarkable efficacy in treating cancers driven by aberrant kinase activity. Another strategy is the development of monoclonal antibodies that bind to oncogene products, interfering with their function or promoting immune-mediated destruction of cancer cells. In summary, oncogenes represent a fundamental piece of the intricate puzzle that is cancer biology. Their discovery and elucidation have transformed our understanding of the molecular mechanisms underlying cancer development. Oncogenes can arise from different sources, such as normal cellular genes (proto-oncogenes) that undergo genetic alterations or the acquisition of abnormal signaling properties. Proto-oncogenes encode proteins that regulate various cellular processes, including cell growth, proliferation, differentiation, and survival. Notable examples of oncogenes include Human Epidermal Growth Factor Receptor 2 (*HER2*), Kirsten Rat Sarcoma Viral Oncogene Homolog (*KRAS*), and B-cell Lymphoma 2 (*BCL2*), among others. Mutations or abnormalities in proto-oncogenes can transform them into oncogenes, leading to uncontrolled cell growth and cancer development. Oncogenes can be broadly classified into several categories based on their functional properties. Some oncogenes encode growth factors or their receptors, while others regulate intracellular signaling pathways that govern cell growth and survival. Additionally, there are oncogenes involved in cell cycle regulation, DNA repair, and apoptosis.